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Abstract
Background: Clonorchiasis, a food-borne zoonosis, is caused by Clonorchis sinensis. The intestinal tract and bile
ducts are crucial places for C. sinensis metacercariae to develop into adult worms. The endospore of Bacillus subtilis
is an ideal oral immunization vehicle for delivery of heterologous antigens to intestine. Cysteine protease of C.
sinensis (CsCP) is an endogenous key component in the excystment of metacercariae and other physiological or
pathological processes.
Methods: We constructed a fusion gene of CotC (a coat protein)-CsCP and obtained B. subtilis spores with recombinant
plasmid of pEB03-CotC-CsCP (B.s-CotC-CsCP). CotC-CsCP expressed on spores’ surface was detected by Western blotting
and immunofluorescence. Immunological characteristics of recombinant spore coat protein were evaluated in a mouse
model. The levels of CsCP-specific antibodies were detected by ELISA. Effects of recombinant spores on mouse intestine
were evaluated by histological staining. The activities of biochemical enzymes in serum were assayed by microplate.
Liver sections of infected mice were evaluated by Ishak score after Masson’s trichrome.
Results: The B.s-CotC-CsCP spores displayed CsCP on their coat. Specific IgG and isotypes were significantly induced
by coat proteins of B.s-CotC-CsCP spores after subcutaneous immunization. IgA levels in intestinal mucus and bile of
B.s-CotC-CsCP orally treated mice significantly increased. Additionally, more IgA-secreting cells were observed in
enteraden and lamina propria regions of the mouse jejunum, and an increased amount of acidic mucins in intestines
were also observed. There were no significant differences in enzyme levels of serum among groups. No inflammatory
injury was observed in the intestinal tissues of each group. The degree of liver fibrosis was significantly reduced after
oral immunization with B.s-CotC-CsCP spores.
Conclusions: Bacillus subtilis spores maintained the original excellent immunogenicity of CsCP expressed on their
surface. Both local and systemic specific immune responses were elicited by oral administration of B.s-CotC-CsCP spores.
The spores effectively promoted intestinal health by inducing secretion of acidic mucins, with no other side effects to
the liver or intestine. Oral administration of spores expressing CsCP could provide effective protection against C. sinensis.
This study may be a cornerstone for development of antiparasitic agents or vaccines against clonorchiasis based on B.
subtilis spore expressing CsCP on the surface.
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Background
Clonorchiasis caused by Clonorchis sinensis is recognized
as an important emergent or re-emergent human food-
borne parasitic disease, one of the most common zoo-
noses in East Asia. Humans or animals can be infected
mainly due to ingestion of raw or undercooked fresh-
water fish containing encysted metacercaria of C. sinen-
sis [1, 2]. Metacercariae excyst in the duodenum of the
host, then migrate into the bile duct, and further develop
into adult worms [2]. Mechanical irritation, immuno-
pathological processes and DNA damage caused by C.
sinensis can induce hyperplasia of the bile duct epithe-
lium and connective tissue and cause jaundice, indiges-
tion, biliary inflammation and bile duct obstruction,
even cholangiocarcinoma (CCA), liver cirrhosis and liver
cancer in humans [1, 3]. Clonorchiasis has become a se-
vere disease burden and brought serious medical and
economic problems to the low- or middle-income coun-
tries of East Asia. It is estimated that more than 200 mil-
lion people are threatened by C. sinensis infection, and
over 15 million people are infected worldwide [2, 4]. The
global burden of clonorchiasis is nearly 275,370 disability
adjusted life years (DALYs), and 5,591 people have died
from this infection every year [4]. It is urgent that effect-
ive prevention strategies such as vaccine trials, the devel-
opment of antiparasitic agents and new health education
be implemented.
Improvement of mucosal immunity is very important
in conferring protection against pathogens (e.g. internal
parasites) that typically invade via mucosal system [5, 6].
Oral immunization, for example, is a very straightfor-
ward, inexpensive and needle-free approach to deliver a
vaccine to the mucosal lining of the gut and elicit
protective immunity within the gut mucosa. However,
oral immunization suffers from degradation by gastric
acid and proteolysis in gastrointestinal tract, which
generates a poor immune response [6, 7]. Therefore,
effective heterologous antigen carriers should be
chosen to solve the problem of limited absorption
and tolerance in the gut.
A series of reports indicated that the endospore of
Bacillus subtilis is an ideal vehicle for delivery of heter-
ologous antigens to the gastrointestinal tract. First,
spore-forming B. subtilis is a non-pathogenic and non-
invasive aerobic Gram-positive bacterium [8, 9]. Spores
of various Bacillus species are currently being used as
probiotics and food supplements in both humans and ani-
mals [9, 10]. They can survive under extreme temperature,
desiccation, pH and exposure to noxious chemicals and
solvents [11, 12]. In addition, these spores possess con-
venient gene operability. Heterologous antigens can be
stably and sufficiently displayed on the surface of spores
using the outer coat proteins of the B. subtilis spore (such
as CotB, CotC and CotG) as the fusion partner [12, 13]. In
our laboratory, the oral immunization delivery platform
based on a B. subtilis spore-engineering system has been
successfully constructed and is proven to be valid and
feasible [14–16].
The cysteine protease superfamily of parasite organ-
isms plays a key role in physiology and related patho-
biology processes that are closely related to larval
migration, nutrition acquisition, egg hatching and im-
mune evasion [3, 17–19]. Currently, cysteine prote-
ases identified from various parasites (e.g. C. sinensis,
Fasciola hepatica, Taenia solium and Ancylostoma
caninum) have been exploited as major potential mol-
ecules for serodiagnosis, immuno-/chemo-therapy and
vaccine candidates [19–25]. The cysteine protease from C.
sinensis (CsCP) is an important component of excretory-
secretory products (ESPs) in both adult worms and meta-
cercariae [19, 26]. Additionally, CsCP is an indispensable
protease participating in the excystment of metacercariae,
enabling larvae to successfully move to bile ducts,
and further develop into adults [26]. Therefore, CsCP
will be a potential target for effective vaccines and
drug development.
In the present report, the encoding sequence of CsCP
was transformed into B. subtilis (WB600) using an
Escherichia coli/B. subtilis shuttle vector. The CotC-
CsCP fusion gene was constructed and expressed on
spore coat. Mice were administered subcutaneously with
coat proteins extracted from CotC-CsCP-transformed B.
subtilis (B.s-CotC-CsCP) spores or recombinant CsCP
protein purified from an E. coli expression system
(rCsCP). The evoked immune reactions were compared.
Additionally, the specific local and systemic immune
responses triggered by B.s-CotC-CsCP spores were
analysed, as were the effects on the intestinal environ-
ment in mice after oral administration of B.s-CotC-
CsCP spores.
Methods
Expression and purification of rCsCP
The coding sequence of CsCP (accession number
JN655695), minus the signal sequence, was amplified
from a C. sinensis cDNA library and cloned into the
pET-28a (+) vector. The recombinant plasmid was
transformed into E. coli BL21 (DE3) (BL21-pET28a-
CsCP, abbreviated as BL21-CsCP) and induced by iso-
propyl β-D-thiogalactopyranoside (IPTG) as described
previously [19]. The induced E. coli was collected by
centrifugation and ultrasonicated to obtain inclusion
bodies in sediment. The inclusion bodies were dis-
solved in phosphate-buffered saline (PBS) containing
2, 4 and 6 M urea, and rCsCP was released into the
supernatant. Finally, rCsCP was purified with the His
Bind Purification kit (Novagen, Darmstadt, Germany), and
gradient elution with 5–400 mM imidazole [15, 19].
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The construction of B.s-CotC-CsCP
The coding sequence of coat protein C (CotC) from B.
subtilis spores, a protein over-expressed on spore sur-
face, was amplified by polymerase chain reaction (PCR)
using specific primers (F: 5′-CAT GTC GAC TGT
AGG ATA AAT CGT T-3′, R: 5′-CGG AAG CTT
GTA GTG TTT TTT ATG C-3′, where the underlined
portions are restriction sites for Sal I and Hind III).
The DNA sequence was inserted into the multiple
clone site of the pBluescript II SK (−) plasmid [15, 27]
after digestion with Sal I and Hind III. The coding se-
quence of CsCP was amplified from the previously con-
structed pET28a (+)-CsCP plasmid using specific
primers (F: 5′-CCC AAG CTT AGC AAC ATT CCT
GAA TCA G-3′, R: 5′- TAC GAG CTC TCA CAA
GAT GAT CGA GGT G-3′) containing restriction sites
for Hind III and Sac I (underlined). The sequence was
inserted into pBluescript II SK (−)-CotC plasmid,
followed by CotC using Hind III and Sac I restriction
sites, and transformed into E. coli DH5α (Promega,
Madison, USA). Finally, the CotC- CsCP fusion gene
was sub-cloned into a pEB03 shuttle vector after digest-
ing with Sal I and Sac I. The recombinant plasmid of
pEB03-CotC-CsCP was colony-formed in DH5a and
easily electro-transformed into B. subtilis WB600 to
construct B.s-CotC-CsCP. Similarly, B. subtilis WB600
with the pEB03-CotC plasmid (B.s-CotC) was obtained
by electro-transformation using specific primers (F: 5′-
CAG AAG CTT TGT AGG ATA AAT CGT T-3′, R:
5′-CGC GAG CTC TTA GTA GTG TTT ATG C-3′,
restriction sites underlined). All recombinant plasmids
above were confirmed by sequencing.
Preparation of spores and coat proteins
Bacillus subtilis WB600 with pEB03-CotC-CsCP was
cultured in Difco Sporulation Medium (DSM, BD,
Franklin Lakes, USA), and the spores were obtained by
the exhaustion method as described previously [28].
After incubation for 24 h, the spores were harvested by
centrifugation, treated with 1 mM phenylmethylsulfonyl
fluoride (PMSF) plus 4 mg/ml lysozyme for 30 min at
room temperature (RT), washed with 1 M NaCl and
1 M KCl, and washed twice with distilled water. Finally,
the spores were re-suspended in sterile water and
treated in a 68 °C water bath for 1 h to kill the residual
WB600 propagules. To extract the coat proteins of
spores, the induced spores were treated with sodium
dodecyl sulfate (SDS)-dithiothreitol (DTT) extraction
buffer (0.5% SDS, 0.1 M DTT, 0.1 M NaCl) at 37 °C for
2 h, washed with 1 M Tris-HCl buffer (pH 8.0) six
times, and suspended in 5 ml broken buffer (50 mM
Tris-HCl, 0.5 mM EDTA, 1 mM PMSF) and ultrasoni-
cated for 5 min. Coat proteins were collected from the
precipitate after centrifugation.
SDS-PAGE, Western blotting and mass spectrometry analysis
The spores induced at different time points (0 h, 6 h, 12 h
and 24 h) and the precipitate/supernatant of the sonicated
lysates were analysed by 12.0% SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) to evaluate the expression of
the CotC-CsCP fusion protein. The separated proteins
were transferred onto polyvinylidene fluoride (PVDF)
membranes for Western blotting analysis. The membranes
were blocked with 5% non-fat milk in phosphate buffer sa-
line containing 0.05% Tween 20 (PBS-T) for 2 h at RT and
incubated with rat anti-rCsCP serum (1:600) overnight at
4 °C. After washing three times in PBS-T, the membranes
were incubated with HRP-conjugated rabbit anti-rat IgG
(1:2000, Sigma, St. Louis, USA) for 1 h at RT and were de-
tected by enhanced chemiluminescence (ECL). Meanwhile,
the induced spores containing pEB03-CotC-CsCP or
pEB03-CotC, BL21 with pET-28a-CsCP and purified
rCsCP from BL21 were comparatively analysed by 12%
SDS-PAGE. The corresponding bands of purified rCsCP
and CotC-CsCP fusion protein in the polyacrylamide gel
were cut out, digested with trypsin and injected onto an
ABI 4800 Proteomics Analyzer Matrix-assisted laser de-
sorption ionization time-of-flight mass spectrometer
(MALDI-TOF-MS/MS) and Mascot search engine (Matrix
Science, London, UK) for protein identification.
Immunofluorescence and fluorescent confocal microscopy
To confirm whether CsCP displayed on the surface of
spores, 200 μl of the treated sporulation suspension was
fixed onto slides according to improved methods previ-
ously described [14, 15]. Samples were blocked with
normal goat serum for 2 h at RT and incubated with rat
anti-rCsCP serum (1:200) overnight at 4 °C. Following
three PBS washes, Cy3-labeled goat anti-rat IgG (1:400,
Invitrogen, Carlsbad, USA) was used to cover the sam-
ples smears for 1 h at RT (in dark). The samples were
incubated for 3–5 min with a 4′, 6-diamidino-2-pheny-
lindole-(DAPI)-DNA staining solution. Fluorescent im-
ages were captured using a Leica DMI4000B fluorescent
microscope and a ZEISS LSM 510 META confocal
microscope. The induced spores containing pEB03-CotC
served as the control.
Immunogenicity analysis of subcutaneously immunized
rCsCP and B.s-CotC-CsCP
Female BALB/c mice aged 6–8 weeks were purchased
from the Animal Center of Sun Yat-Sen University and
raised carefully in accordance with the animal care and
the ethical guidelines of the National Institutes of Health.
Each BALB/c mouse was immunized subcutaneously
(s.c.) with 100 μg rCsCP or the coat proteins of the B.s-
CotC-CsCP spore, which were emulsified with complete
Freund’s adjuvant (Sigma-Aldrich, St. Louis, USA) at the
first injection. Control mice were similarly administered
Tang et al. Parasites & Vectors  (2016) 9:648 Page 3 of 14
with an equal volume of PBS plus adjuvant. Two booster
injections at 2-week intervals were performed with
50 μg of proteins or an equal volume of PBS emulsified
in incomplete Freund’s adjuvant (Sigma-Aldrich, St.
Louis, USA). Anti-sera were collected every 2 weeks for
4 weeks (Fig. 1a) after the final boosting, and antibody
titres were determined by ELISA. All anti-sera samples
were split and stored at -80 °C.
Animals, oral immunization and sample collection
Sixty mice were randomly and evenly divided into the
following four groups as B.s-CotC-CsCP, BL21-CsCP,
B.s-CotC and PBS. Mice were administered orally by
gavage with spores (1 × 109), BL21-CsCP (equivalent
CsCP as expressed by the spores), and PBS in a volume
of 0.20 ml. Mice were treated three times in total (3 days
each time) at biweekly intervals (Fig. 1b).
Serum samples were collected on days 5, 7, 10 and 14
after each administration. Mice were sacrificed two weeks
after each oral treatment. The small intestines were isolated
and washed 2–3 times with 0.4 ml sterile PBS. The residual
mucus was scraped using tweezers. Gallbladders were also
collected. The midsection of mouse jejuna (approximately
5–7 mm) was excised and immersed in Bouin’s solution
(75% saturated picric acid solution, 25% formalin and 5%
glacial acetic acid) for 24 h before histological analysis.
Detection of CsCP-specific antibodies by indirect ELISA
The levels of IgG, IgG1 and IgG2a in serum were mea-
sured by an ELISA assay as described previously [15, 27].
Plates were coated with 5 μg/ml purified rCsCP (0.05 M
carbonate-bicarbonate buffer, pH 9.6) at 100 μl per well
and incubated at 4 °C overnight. After washing with PBS-
T three times, the plates were blocked with 5% skimmed
milk for 2 h at 37 °C. After washing routine program, the
plates were incubated with serum samples (1:100) for 2 h
at 37 °C and subsequently with HRP-conjugated goat anti-
mouse IgG (1:2000, Santa Cruz, USA), IgG1 (1:2000, Santa
Cruz, USA), or IgG2a (1:2000, Invitrogen, Carlsbad, USA),
respectively, for 1 h at RT. Next, 100 μl tetramethylbenzi-
dine (TMB, BD, Franklin Lakes, USA) solution was added
to the plates for 10–15 min and stopped by 50 μl of 2 M
H2SO4, and the absorbance was detected at 450 nm. Be-
fore changing the incubation solution, the plates were
washed with PBS-T 3 times.
Similarly, IgA levels in sera (1:20), intestinal lavage
mucus (1:20), and bile (1:100) were also detected.
HRP-conjugated goat anti-mouse IgA (1:2000, Southern
Biotech, Birmingham, USA) was employed as a secondary
antibody.
Challenge infections and protective efficacy evaluation
Metacercariae of C. sinensis were isolated from Pseudoras-
bora parva, captured in Shuangfeng county, Hunan, as
previously described [14, 15]. Two weeks after final
booster, orally immunized mice (n = 5 for each group)
were challenged with 30 living C. sinensis metacercariae
through intragastric administration. All mice were sacri-
ficed at 6 weeks post-challenge infection. Liver tissues
were isolated and submitted to histopathological staining.
Fig. 1 Schematic of the treatment regimen. a Subcutaneous immunization of mice with emulsified PBS, rCsCP or spore coat proteins of B. s-CotC-
CsCP administered three times. Serum samples were collected at 2, 4, 6 and 8 weeks. b Oral administration of mice with PBS, spores of B.s-CotC
or B.s-CotC-CP, or BL21-CP three times in total, with continuous gavage for three days each time. Serum, intestine and bile samples were collected
every 2 weeks. Additionally, serum samples were collected on days 5 and 10 after each administration. Abbreviations: B.s-CotC-CP, WB600 containing
pEB03-CotC-CsCP; B.s-CotC, WB600 harbouring pEB03-CotC; BL21-CP, BL21 harbouring pET28a-CsCP
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Histology staining
After incubation with Bouin’s solution, mouse jejuna
from each group were dehydrated, embedded in paraffin
wax and sliced into 5-μm sections. The sections were
rehydrated with xylene and a gradient ethanol, followed
by PBS-T washing. After paraffin removal, the endogen-
ous peroxidase sections were removed by using 3%
hydrogen peroxide. The sections were soaked in 0.01 M
citrate buffer to retrieve the antigens by high-pressure
boiling for 10 min. The slides were blocked with normal
goat serum for 1 h at RT, and incubated with goat anti-
mouse IgA (1:600, Southern Biotech, Birmingham, USA)
overnight at 4 °C. After washing three times with PBS,
the slides were incubated with HRP-Protein A (1:4000,
Invitrogen, Carlsbad, USA) at RT for 1 h. The immuno-
reactive signal was developed using 3, 3′-diaminobenzi-
dine (DAB, ZSGB-BIO, China). Finally, the slides were
stained with Mayer’s haematoxylin, dehydrated and
mounted with neutral balsam. Images were captured
under a light microscope (Carl Zeiss, Germany).
For pathological observations, the jejunum sections
were stained with routine haematoxylin and eosin (HE).
Liver tissue sections from C. sinensis metacercariae
infected mice were performed with routine Masson
staining. All specimens were viewed under a light micro-
scope (Carl Zeiss, Germany). Liver fibrosis of each group
was morphologically evaluated by using the Ishak fibro-
sis score [29].
The mucus production of jejunum was evaluated using
alcian blue-periodic acid Schiff reagent (AB-PAS, Baso,
China) according to the manufacturer’s protocol. Mucins
were observed under a light microscope (Carl Zeiss,
Germany).
Detection of biochemical indices
The serum of each group was collected at week 6.
Glutamic pyruvic transaminase/alanine aminotransferase
(GPT/ALT) and glutamic oxaloacetic transaminase/aspar-
tate aminotransferase (GOT/AST) were measured using
an alanine aminotransferase assay Kit and an aspartate
aminotransferase assay Kit, respectively (Jiancheng, China).
Statistical analysis
Experimental data were presented as the mean ± standard
deviation (SD) values. Student’s t-test was performed to
determine significant differences between groups using
SPSS software 13.0 software. P-values < 0.05 were consid-
ered as statistically significant.
Results
Expression and identification of fusion/recombinant protein
The recombinant plasmids pEB03-CotC and pEB03-
CotC-CsCP were successfully constructed and sub-cloned
into WB600 (Additional file 1: Figure S1). The rCsCP
protein was overexpressed in IPTG-induced BL-21 con-
taining pET28a-CsCP, and purified with gradient imid-
azole (Additional file 1: Figure S1, Additional file 2: Figure
S2).
The molecular mass of the CotC-CsCP fusion protein
was approximately 43.8 kDa, corresponding to the mo-
lecular mass of CsCP (35 kDa) plus CotC (8.8 kDa). As
shown in Fig. 2, the CotC-CsCP fusion protein abundantly
expressed in the DSM medium induced B.s-CotC-CsCP
spores, while no matching band was observed in the
medium of B.s-CotC spores. The expression of the fusion
protein gradually increased with incubation time (Fig. 2b).
In addition, the spore coat proteins contained large
amounts of CotC-CsCP in the precipitation extract but
almost no corresponding band was present in the super-
natant (Fig. 2c). Western blotting analysis using rat anti-
rCsCP serum as the primary antibody showed specific
bands at 43.8 kDa in spores samples incubated for 6 h,
12 h and 24 h as well as for coat protein precipitation;
however, no bands were observed in propagules and
supernatant (Fig. 2f, g).
The mass spectrum analysis of CotC-CsCP and rCsCP
is shown in Fig. 2. Both proteins were identified as the
cysteine protease of C. sinensis and belonged to Pro-
Cathepsin L (Table 1).
Immunofluorescence analysis of CsCP expressed on the
spore surface
Using the rat anti-rCsCP serum as the primary antibody
and followed by Cy3-labelled goat anti-rat IgG as the
secondary antibody, immunofluorescence and fluores-
cent confocal microscopy showed that red fluorescence
abundantly distributed surrounded the spores’ coat of
B.s-CotC-CsCP with a high positive rate (Fig. 3a, b). Al-
most no red fluorescence was visualized on the B.s-CotC
spores surface (Fig. 3c).
Specific IgG and isotypes in serum of subcutaneous
immunized mice
The rCsCP protein provoked markedly higher production
of specific IgG compared with the control group only
2 weeks after the first immunization (t(2) = 14.72, P = 0.005).
The significantly higher levels of anti-rCsCP IgG continued
rising until four weeks after the last immunization (t(2) =
351.27, P = 10-9). The titre of anti-rCsCP IgG reached
1:206,400 at 6 weeks after immunization (Fig. 4a, b).
After subcutaneous administration of rCsCP, the spe-
cific IgG1 level remarkably increased at week 2 (t(2) =
49.00, P = 10-9), while the IgG2a level showed obvious
differences at week 4 (t(2) = 64.56, P = 10
-9), and both
reached their peak at week 6 (Fig. 4c).
The specific IgG and IgG1/IgG2a isotype antibodies
were induced by coat proteins extracted from B.s-CotC-
CsCP spores. The IgG level significantly increased from
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two to eight weeks after immunization, and the titre of
specific IgG reached 1:1600 at week 6 (Fig. 4d, e). The spe-
cific IgG1 and IgG2a levels were significantly different
compared with those in the PBS group at week 4 and
week 6 (Fig. 4f).
CsCP-specific antibodies in orally administered mice
The specific IgG level in sera from B.s-CotC-CsCP group
mice was significantly higher than of the PBS group after
day 19 (t(2) = 4.66, P = 0.043) and reached peak titre on
day 24 (t(2) = 39, P = 0.001). The level was significantly
Table 1 MALDI-TOF MS/MS identification results of the proteins from CotC-CsCP and rCsCP
Sample Protein name MW (Da) Protein PI Protein score P-value Peptides matched Swiss Prot Accession number
CotC-CsCP C. sinensis cysteine protease precursor 35,838 5.11 163 1e-16 11 2o6x.1.A gi|351693702
rCsCP C. sinensis cysteine protease precursor 35,383 5.11 159 2.5e-16 11 2o6x.1.A gi|351693702
Fig. 2 Expression and identification of rCsCP and CotC-CsCP. a SDS-PAGE analysis of CsCP expressed in E. coli BL21 and B. subtilis spores. The
molecular mass of CotC-CsCP fusion protein was approximately 43.8 kDa. Abbreviations: B.s-CotC-CP, WB600 containing pEB03-CotC-CsCP; B.s-CotC,
WB600 harbouring pEB03-CotC; BL21-CP, BL21 harbouring pET28a-CsCP; rCP, purified rCsCP. b The expression of CotC-CsCP fusion protein at different
sporulation times by 12% SDS-PAGE. c Total spore coat proteins extracted from recombinant spores (pEB03-CotC-CsCP) by SDS-PAGE analysis.
d Identification of CotC-CsCP fusion protein by MS. e MALDI-TOF/TOF-MS analysis of purified rCsCP. f Expression identification of CotC-CsCP fusion protein
at different sporulation times by Western blotting using rat anti-rCsCP serum. g Total coat proteins of pEB03-CotC-CsCP spore recognized by rat anti-rCsCP
serum using Western blotting. Abbreviations: P, precipitation; S, supernatant
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different than the BL21-CsCP group on day 24 and at week
6 (Fig. 5a). Specific IgG1 and IgG2a levels in the B.s-CotC-
CsCP group were remarkably elevated at weeks 2 and 4,
respectively. The levels of IgG1 were significantly different
between the B.s-CotC-CsCP and BL21-CsCP groups at
week 4 (Fig. 5b). Specific IgA levels in the sera of the B.s-
CotC-CsCP mice were significantly higher than PBS group
after week 4 (t(2) =5, P = 0.038) (Fig. 5c). At some points,
the levels of anti-CsCP IgG, IgG1/IgG2a and IgA in serum
significantly differed between BL21-CsCP group and PBS
group. However, no significant difference was detected
between the CotC group and the PBS group (Fig. 5).
Compared with the other three groups, specific IgG
levels in intestinal mucus of B.s-CotC-CsCP group were
relatively higher, and significantly elevated at week 6 (t(2)
= 4.33, P = 0.049) (Fig. 5d). Specific IgA levels in both
intestinal mucus and bile of B.s-CotC-CsCP group were
significantly higher than PBS group at week 4 and week 6,
respectively, and showed significant difference compared
with BL21-CsCP group at the same time (Fig. 5e, f ).
IgA-secreting cells and mucosubstance in intestine
After incubation with goat anti-mouse IgA and HRP-
protein A, the sIgA cells in mouse intestine were observed
by DAB staining (positive cells were indicated by dark
brown). Compared with the other three groups, a large
number of dark brown-stained cells were distributed in
the enteraden and lamina propria regions of the mouse
jejunum in the B.s-CotC-CsCP group (P = 10-9; Fig. 6).
After staining the slides with alcian blue and periodic
acid-Schiff, many acidic mucins (marked in blue) were
found in the intestines of the B.s-CotC and B.s-CotC-
CsCP groups. A small amount of acidic mucins were
also found in the BL21-CsCP group, while copious neu-
tral and alkaline mucus (indicated by amaranth) was
present in the PBS group at week 4 (Fig. 7). Two weeks
after the last immunization (week 6), a large amount of
acidic mucosubstance was released from goblet cells in
the B.s-CotC-CsCP group (Fig. 7).
Biochemical index and histological analysis
There was no significant difference in GPT/ALT and
GOT/AST levels in serum amongst the groups (Fig. 8).
In addition, no inflammatory injury was observed in the
intestinal tissues of each group using haematoxylin-eosin
staining (Additional file 3: Figure S3).
Protective efficacy evaluation
Six weeks post-challenge infection, livers of all mice were
sent to Masson staining. As shown in Fig. 9, compared
Fig. 3 Expression identification of CsCP on the coat of recombinant spores by immunofluorescence. The B. subtilis spores with pEB03-CotC-CsCP
were observed by immunofluorescence (a) and confocal laser microscope (b) after incubating with rat anti-CsCP serum and Cy3 labeled goat anti-rat
IgG (red). The nucleus was stained with DAPI (blue). Sporulation CotC strain treated with the same method and both visualized under fluorescent light
(c). All spores above were observed under bright field (BF) as well. Abbreviations: B.s-CotC-CP, WB600 containing pEB03-CotC-CsCP; B.s-CotC, WB600
harbouring pEB03-CotC. Scale-bars: a, c, 50 μm; b, 2 μm
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with other groups, recombinant spores expressing CsCP
administered mice had a lighter collagen deposition in the
bile duct or hepatic parenchyma, and exhibited no obvious
phenomenon of bile duct hyperplasia. Sections of adult
worm were observed in some slides from mice of control
groups but not in that from B.s-CotC-CsCP group. Ishak
scores demonstrated that the degree of hepatic fibrosis
could be significantly reduced after orally treated with
spores of pEB03-CotC-CsCP (Fig. 9e).
Discussion
In the current study, we constructed a recombinant
plasmid of pEB03-CotC-CsCP that could display original
CsCP on the coat of B. subtilis WB600 spore. The spe-
cific IgG was significantly induced by coat proteins ex-
tracted from B.s-CotC-CsCP spores after subcutaneous
immunization. Compared with control groups, IgA
levels in the serum, intestinal mucus and bile of the B.s-
CotC-CsCP orally treated mice increased remarkably. A
larger number of IgA-secreting cells were observed in
the enteraden and lamina propria regions of the mouse
jejunum in the B.s-CotC-CsCP group. More acidic mu-
cins and mucosubstance were found in the intestines of
the B.s-CotC-CsCP group. Moreover, there was no sig-
nificant difference in the GPT/ALT and GOT/AST levels
in the sera from each group. No inflammatory injury
was observed in the intestinal tissues of each group too.
The CotC-CsCP fusion protein was abundantly
expressed with extended induction time. SDS-PAGE and
Western blotting showed that an obvious protein band
at approximately 43.8 kDa appeared in the B.s-CotC-
CsCP sample, and could be specifically recognized by
anti-rCsCP rat sera (Fig. 2). In addition, we confirmed
that CsCP in the fusion protein presented by B. subtilis
spores is similar to rCsCP purified from E. coil using
mass spectrometry (Fig. 2). Immunofluorescence and
confocal results clearly revealed that CsCP were
enriched around the outer coat of spores (Fig. 3). This
observation indicates that the stable spore delivery sys-
tem was successfully exploited to express CsCP, and the
CotC-CsCP fusion protein could directly contact the
intestinal tract after oral administration.
In subcutaneously immunized mice, the antibody titres
of CsCP specific IgG reached 1:206,400 after three im-
munizations with rCsCP plus adjuvant (Fig. 4b). It dem-
onstrated that rCsCP elicited high levels of specific
Fig. 4 Antibody titres of IgG and isotopes triggered by rCsCP and coat proteins of B.s-CotC-CsCP spores via subcutaneous immunization route.
ELISA evaluation of the CsCP specific IgG a and IgG1/IgG2a c levels in mouse sera after subcutaneous immunization with rCsCP. b Antibody titres
of IgG induced by rCsCP at week 6. The levels of CsCP specific IgG d and IgG1/IgG2a f in the sera of mice subcutaneously immunized with spore
coat proteins of B.s-CotC-CsCP. Antibody titres of IgG evoked by spore coat proteins of at week 6 were also assayed by ELISA e. Data were
displayed as the mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001. Abbreviations: B.s-CotC-CP, WB600 containing pEB03-CotC-CsCP; B.s-CotC, WB600
containing pEB03-CotC; rCP, purified rCsCP
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antibody rapidly and verified that CsCP was of strong
immunogenicity. When mice were administered with
rCsCP, the specific IgG1 level in the serum significantly
increased after week 2 and continued rising, while IgG2a
levels were significantly elevated after week 4 (Fig. 4c).
In mice treated with coat proteins extracted from the
B.s-CotC-CsCP spore, the antibody titres of the specific
IgG in serum reached 1:1600 at week 6. IgG1 and IgG2a
levels significantly increased at weeks 4 and 6. The
IgG2a level at week 4 was higher than that of IgG1, but
the levels were inversed at week 6 (Fig. 4d-f ). Compared
with rCsCP, the specific antibody titres induced by the
coat proteins of the B.s-CotC-CsCP spore were relatively
lower. This result may have occurred because the coat
proteins of the B.s-CotC-CsCP spore were isolated from
the precipitation of spore lysate, which contained many
other proteins in addition to CsCP (Fig. 2c). Addition-
ally, an insoluble mixture might trigger a poorer im-
mune response than soluble antigen with subcutaneous
administration. The IgG1 antibody response generally
represents helper T (Th) 2-mediated humoral immunity,
while IgG2a represents Th1-mediated immunity [30, 31].
Our results showed that both the rCsCP and coat pro-
teins of the B.s-CotC-CsCP spore could elicit Th1/Th2
combined immune responses in mice, but rCsCP
induced a Th2 dominant response. There was no ques-
tion as to the coat proteins of the B.s-CotC-CsCP spore.
Collectively, these data demonstrated that CsCP deliv-
ered by B. subtilis spores maintain the immunogenicity
and effectively induce an immune response in mice.
Clonorchis sinensis metacercariae excyst in the duode-
num of the definitive host and develop into larvae within
a few minutes. Larvae rapidly migrate into bile ducts,
and further maturate into adults [1, 2], so that during
the invasion and parasitism, both the intestinal tract and
the bile duct are important places for the development
and growth of C. sinensis. This behaviour suggests that
intervention measures applied in these two locations
may be effective against C. sinensis infection. Cysteine
proteases mainly distribute to the excretory bladder and
the excretory granules of metacercariae. The cysteine
protease family is one of the most abundantly expressed
protease families in many digenetic trematode parasites
(e.g. C. sinensis, Schistosoma japonicum, Clinostomum
complanatum, Fasciola hepatica and Euclinostomum
heterostomum) [18]. Moreover, cysteine protease is a key
intrinsic endogenous enzyme that participates in the
process of metacercariae excystment, invasion and im-
mune modulation [18, 26, 32, 33]. Collectively, cysteine
protease is considered to be a potential candidate
Fig. 5 ELISA assay of immune responses triggered by the oral administration of recombinant B. subtilis spores. Specific IgG (a), IgG1/IgG2a (b),
and IgA (c) levels in sera from mice orally treated with pEB03-CotC-CsCP- or pEB03-CotC-transformed spores, BL21-CsCP and PBS were detected.
CsCP-specific IgG (d) and sIgA (e) levels in intestinal mucous and sIgA level in bile (f) were analysed. Data are expressed as the mean ± SD. Statistical
significance was analysed by the Student’s t-test (*P < 0.05; **P < 0.01). Abbreviations: B.s-CotC-CP, WB600 containing pEB03-CotC-CsCP; B.s-CotC, WB600
containing pEB03-CotC; BL21-CP, BL21 harbouring pET28a-CsCP
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molecule for the development of oral vaccine against C.
sinensis infection.
Spores, the quiescent cell form of B. subtilis, are an
ideal vehicle for delivery of heterologous antigens in the
gastrointestinal tract because they are probiotics and re-
sistant to extreme environments. They have previously
served as effective adjuvants as well [15, 16, 34]. Bacillus
subtilis spores (approximately 1.2 μm in length) are well
uptaken by M cells, transported into Peyer’s patches,
processed by antigen-presenting cells, presented to B
cells or T cells, and are transported to other gut-
associated lymphoid tissues (GALTs) and systemic
lymphoid tissues [14, 35]. During this process, a series of
antigen-specific immune responses are induced and
abundant immune globulins are secreted by plasma cells
[36]. As sIgA is the most abundantly produced immuno-
globulin in the mammal mucosal system, it can serve as
the first line of defence in protecting the intestinal epi-
thelium from pathogenic microorganisms and enteric
toxins [37, 38]. In addition, sIgA promotes the clearance
of pathogenic microorganisms and antigens by blocking
their access to epithelial receptors, entrapping them in
mucus, and facilitating their removal by peristaltic and
mucociliary activities [38]. Our results show that CsCP
recombinant spores evoked plenty of specific sIgA in in-
testinal mucosa and bile (Fig. 5e, f ). A large number of
IgA-secreting cells were observed in the jejunum of B.
subtilis spores in orally administered mice, especially in
the B.s-CotC-CsCP group (Fig. 6). IgA-secreting cells
were primarily intestinal epithelial and lamina propria
lymphocytes distributed in the enteraden and intestinal
villus (Fig. 6). In addition, specific IgG arouse in intes-
tinal mucus of B.s-CotC-CsCP group (Fig. 5d). More-
over, the levels of IgG, IgG1/IgG2a and IgA in the serum
of the B.s-CotC-CsCP group were significantly higher
than the control group (Fig. 5a-c). These results demon-
strated that both local mucosal and systemic humoral
immune responses were triggered by the oral adminis-
tration of B.s-CotC-CsCP. Data also confirmed that the
spores carried antigens that could trigger higher levels of
specific antibody and be more suitable than E. coli for
the development of oral vaccine vehicles carrying heter-
ologous proteins.
Bacillus subtilis spores are probiotic microorganism
that are used as a food supplement and can promote
intestinal health (e.g. aiding in digestion and being
Fig. 6 Immunohistochemistry analysis of IgA-secreting cells in the intestinal epithelium of orally immunized mice. IgA-secreting cells were stained
dark brown. The jejuna (approximately 5–7 mm) of each group were isolated and submitted to immunohistochemical staining at week 4. Panels
(a) and (b) represent PBS-treated mice. Panels (c) and (d) represent B.s-CotC orally administered mice. Panels (e) and (f) represent BL21-CsCP
gavaged mice. Panels (g) and (h) represent mice orally administered with spores expressing CotC-CsCP. Scale-bars: a, c, e, g, 200 μm; b, d, f, h,
50 μm. The arrows indicate IgA-secreting cells. i Integrated option density (IOD) of IgA-secreting cells. ***P < 0.001
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Fig. 7 AB-PAS stain of mucins in the intestinal epithelium of oral administration mice. Jejunum tissue sections of each group were collected, fixed, and
stained with AB-PAS. Acid mucins were dyed to blue, neutral mucin were dyed red, and the alkaline and neutral mixed mucins were dyed amaranth.
Panels a-b, c-d, e-f and g-h indicate PBS, B.s-CotC, BL21-CsCP and B.s-CotC-CsCP orally administered groups at week 4, respectively. Panels (i) and (j)
show the B.s-CotC-CsCP group treated at week 6. Scale-bars: a, c, e, g, i, 200 μm; b, d, f, h, j, 50 μm. The arrows indicate acidic mucins secreted by
goblet cells
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beneficial for the balance of intestinal microbiota and
regulation of intestinal mucus environment) [10, 39].
The mucus layer overlaying the epithelium secreted by
the goblet cells of the gastrointestinal tract serves as the
first line of defence against physical and chemical injury
from luminal contents and pathogens and provides a
natural habitat for commensal microbiota [40–42]. Mu-
cins, the major component of mucus, can be broadly
categorized into neutral and acidic chemotypes. High
levels of acidic mucins such as sialomucin and sulfomu-
cin reportedly coincide with maturation of intestinal bar-
rier function and have been implicated in the protection
of the mucosa from pathogens [43, 44]. Microbiota and
microbial products, meanwhile, can modulate the syn-
thesis and secretion of mucins, either by directly activat-
ing diverse signalling cascades or through bioactive
factors generated by epithelial and lamina propria cells
[42]. In our experiments, B. subtilis spores could
Fig. 8 The activity of GPT/ALT and GOT/AST in the serum of oral
immunization mice. The serum in PBS, B.s-CotC, BL21-CsCP and B.s-
CotC-CsCP groups was collected at week 6. The levels of GPT/ALT and
GOT/AST were analysed. Abbreviations: B.s-CotC-CP, WB600 containing
pEB03-CotC-CsCP; B.s-CotC, WB600 of pEB03-CotC; BL21-CP, BL21
harbouring pET28a-CsCP
Fig. 9 Pathological changes of livers from challenge infection mice. Liver sections of each group were stained with Masson’s trichrome. Collagen
fibers are shown in blue. Panels a–d show mice orally treated with PBS, B.s-CotC, BL21-CsCP and B.s-CotC-CsCP, respectively. Panel (e) provides
the statistic of Ishak scores in liver sections from each mouse. *P < 0.05; **P < 0.01. The thick arrows indicate the adult worms of C. sinensis, and
the thin arrows indicate collagen deposition in livers. Scale-bars: 200 μm
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provoke an increase in acidic intestinal mucus (Fig. 7).
Thus, B. subtilis spores may enhance resistance to path-
ogens, and guarantee intestinal health.
It has been documented that B. subtilis spores are safe
food probiotics. No signs of toxicity or virulence were
found in vivo assessments, and no side effects appeared in
the liver function of the rats after oral treatment [10, 16].
Our findings also confirmed that there was no damage to
the liver or intestine of mice after oral administration of B.
subtilis spores (Fig. 8; Additional file 3: Figure S3). Chal-
lenge experiment verified that oral administration of B.
subtilis spores expressing CsCP could effectively fight
against metacercaria C. sinensis infection by reducing the
process of liver fibrosis in mice (Fig. 9).
Conclusions
We confirmed the excellent immunogenicity of CsCP and
B. subtilis spores as an oral delivery vehicle that maintained
their original immunogenicity by displaying CsCP on the
spore surface. Both local and systemic specific immune re-
sponses were elicited by the oral administration of B. subti-
lis spores expressing CsCP. Moreover, the spores could
effectively promote intestinal health by inducing the secre-
tion of acidic mucins with no side effects to the liver or
intestine. Effective protection against C. sinensis was trig-
gered after oral administration of spores expressing CsCP.
This study is a cornerstone for the development of antipar-
asitic agents or vaccines against clonorchiasis based on B.
subtilis spores expressing CsCP on the surface.
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